Prognostic roles of preoperative &alpha;-fetoprotein and des-&gamma;-carboxy prothrombin in hepatocellular carcinoma patients

doi:10.3748/wjg.v21.i16.4933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7824)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

602

WORD

220

HTML

4018

Figures (1-5)

279

Tables (1-6)

189

Sum=5308

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1018

Download

1498

Sum=2516

Apr 28, 2015 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Apr 28, 2015; 21(16): 4933-4945
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4933

Table 1 Characteristics of hepatocellular carcinoma patients with hepatitis B virus infection

Variables	All patients (n = 105)	LL group (n = 55)	HL group (n = 34)	HH group (n = 16)	P value
Age (yr)	62 (57-68)	62 (59-66)	64 (56-70)	63 (56-70)	0.962
Sex, male/female	90/15	48/7	29/5	13/3	0.829
Body mass index (kg/m²)	23.7 ± 3.1	24.0 ± 2.6	23.5 ± 3.3	23.1 ± 4.3	0.691
Open/pure lap/lap-assisted	83/8/14	43/6/6	29/1/4	11/1/4	0.390
Hr
0/S/1/2/3	50/25/14/14/2	34/13/6/2/0	14/10/4/4/2	2/2/4/8/0	< 0.001
Preoperative laboratory values
Aspartate transaminase (U/L)	31 (22-46)	31 (22-41)	30 (25-48)	43 (24-62)	0.153
Alanine transaminase (U/L)	29 (20-39)	32 (17-42)	27 (21-42)	27 (19-52)	0.978
Platelets (× 10⁴/μL)	16.6 ± 13.3	16.4 ± 12.7	16.2 ± 16.2	18.0 ± 8.6	0.168
Serum ALB (g/dL)	3.95 ± 0.46	3.99 ± 0.46	3.87 ± 0.43	3.98 ± 0.53	0.334
PT (%)	93.3 ± 12.2	95.5 ± 11.1	90.3 ± 14.1	92.2 ± 10.6	0.062
Serum TBIL (mg/dL)	0.79 ± 0.44	0.80 ± 0.45	0.85 ± 0.49	0.65 ± 0.24	0.681
ICGR15	9.6 (5.7-14.9)	9.4 (5.9-14.0)	12.5 (5.7-22.5)	8.5 (5.0-14.6)	0.334
AFP (ng/mL)	24.2 (3.8-165.0)	5.2 (2.4-31.1)	45.0 (5.1-246.5)	1950 (753.5-2827.0)	< 0.001
DCP (mAU/mL)	38 (20-364)	22 (15-28)	399 (90-1,667)	4460 (223-34373)	< 0.001
Intraoperative data
Blood loss (mL)	400 (130-660)	360 (110-560)	435 (100-1,040)	880 (130-1330)	0.042
Surgical duration (min)	332 (243-411)	313 (236-370)	361 (243-450)	432 (270-604)	0.020
Blood transfusion
RCC: yes/no (%)	21/84 (20.0%)	4/51 (7.2%)	10/24 (29.4%)	7/9 (43.8%)	0.001
Pathological results
Tumor size (cm)	4.27 ± 3.21	3.26 ± 2.56	4.97 ± 2.71	6.24 ± 4.77	< 0.001
Multiple tumors: yes/no (%)	39/66 (37.1%)	19/36 (34.5%)	15/19 (44.1%)	5/11 (31.3%)	0.575
Vascular invasion: yes/no (%)	34/71 (32.4%)	10/45 (18.2%)	14/20 (41.1%)	10/6 (62.5%)	0.002
Remnant liver: NL/CH/LC	13/47/41	6/23/26	3/17/14	4/7/5	0.464
Histological tumor differentiation
Well/moderately/poorly	14/63/28	11/35/9	3/18/13	0/10/6	0.048
Recurrence within 2 yr after liver resection
Yes/no (%)	50/55 (47.6%)

Data are presented as medians (25^th-75^th percentile range) for skewed distribution and mean ± SD for normal distribution. LL group: AFP values < 529.8 ng/mL and DCP values < 60 mAU/mL; HL group: AFP values > 529.8 ng/mL or DCP values > 60 mAU/mL; HH group: AFP values > 529.8 ng/mL and DCP values > 60 mAU/mL; Open group: Open laparotomy hepatectomy group; Lap group: laparoscopic hepatectomy group; Pure Lap: Pure laparoscopic hepatectomy; Lap-assisted: Laparoscopy-assisted hepatectomy. Hr0: Partial hepatectomy; HrS: Subsegmentectomy; Hr1: Sectionectomy; Hr2: Bisegmentectomy; Hr3: Trisegmentectomy; ALB: Albumin; PT: Prothrombin; TBIL: Total bilirubin; ICGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; DCP: Des-γ-carboxy prothrombin.

Table 2 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis B virus infection

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95%CI	P value	HR	95%CI	P value
Age	0.977	0.952-1.003	0.086
Sex, male	1.077	0.512-2.264	0.843
Preoperative laboratory values
Aspartate transaminase	1.008	1.003-1.013	0.001¹	1.001	0.993-1.010	0.778
Alanine transaminase	0.999	0.989-1.009	0.811
Platelets	1.001	0.979-1.024	0.929
Serum ALB	0.648	0.367-1.142	0.134
PT	0.974	0.953-0.996	0.021¹	0.976	0.946-1.007	0.124
Serum TBIL	2.305	1.346-3.947	0.002¹	4.068	1.586-10.436	0.004¹
ICGR₁₅	1.033	1.008-1.059	0.011¹	0.967	0.919-1.018	0.967
Tumor markers
HH group	3.235	1.673-6.257	< 0.001¹	2.464	1.086-5.587	0.031¹
HL group	2.042	1.164-3.583	0.013¹	1.083	0.497-2.360	0.841
Intraoperative data
Blood loss	1.001	1.000-1.001	0.002¹	1.000	1.000-1.001	0.416
Surgical duration	1.002	1.000-1.004	0.003¹	1.000	0.997-1.003	0.868
Pathologic results
Tumor size	1.148	1.068-1.234	< 0.001¹	1.182	1.059-1.318	0.003¹
Multiple tumors	1.363	1.152-1.612	< 0.001¹	1.336	0.955-1.869	0.091
Vascular invasion	2.088	1.261-3.458	0.004¹	2.624	1.408-4.892	0.002¹

¹Represents statistical significance. HH group: Alpha-fetoprotein values > 529.8 ng/mL and des-gamma-carboxy prothrombin values > 60 mAU/mL; HL group: Alpha-fetoprotein values > 529.8 ng/mL or des-gamma-carboxy prothrombin values > 60 mAU/mL. ALB: Albumin; PT: Prothrombin; TBIL: Total bilirubin; ICGR15: Indocyanine green retention rate at 15 min.

Table 3 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis B virus infection

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95%CI	P value	HR	95%CI	P value
Age	0.996	0.964-1.028	0.797
Sex, male	1.440	0.511-4.056	0.490
Preoperative laboratory values
Aspartate transaminase	1.008	1.002-1.014	0.012¹	1.004	0.992-1.016	0.518
Alanine transaminase	0.992	0.976-1.007	0.296
Platelets	1.015	0.994-1.035	0.158
Serum ALB	0.469	0.234-0.939	0.033
PT	0.975	0.950-1.000	0.051
Serum TBIL	2.249	1.125-4.495	0.022¹	1.584	0.447-5.613	0.476
ICGR₁₅	1.056	1.025-1.087	< 0.001¹	1.040	0.976-1.108	0.229
Tumor markers
HH group	2.985	1.259-7.075	0.013¹	2.274	0.698-7.403	0.173
HL group	2.112	1.054-4.232	0.035¹	1.025	0.390-2.693	0.960
Intraoperative data
Blood loss	1.001	1.001-1.001	< 0.001¹	1.000	1.000-1.001	0.391
Surgical duration	1.004	1.001-1.008	0.005¹	1.002	0.996-1.007	0.534
Pathologic results
Tumor size	1.239	1.133-1.356	< 0.001¹	1.127	0.969-1.310	0.122
Multiple tumors	1.385	1.121-1.711	0.002¹	1.200	0.813-1.772	0.358
Vascular invasion	2.491	1.335-4.647	0.004¹	3.173	1.352-7.447	0.008¹

Table 4 Characteristics of hepatocellular carcinoma patients with hepatitis C virus infection

Variables	All patients (n = 100)	LL group (n = 34)	HL group (n = 39)	HH group (n = 27)	P value
Age (yr)	71 (62-77)	72 (64-77)	70 (62-75)	70 (65-77)	0.766
Sex, male/female	82/18	22/12	29/10	16/11	0.413
Body mass index	23.6 ± 3.6	23.6 ± 2.9	23.8 ± 3.8	23.4 ± 4.1	0.737
Open/Pure Lap/Lap-assisted	77/12/11	26/3/5	27/8/4	24/1/2	0.218
Hr
0/S/1/2/3	57/27/11/2/3	23/8/3/0/0	21/10/5/1/2	13/9/3/1/1	0.784
Preoperative laboratory values
Aspartate transaminase (U/L)	47 (30-64)	41 (23-56)	48 (35-67)	53 (47-71)	0.101
Alanine transaminase (U/L)	38 (26-57)	33 (21-53)	41 (28-57)	42 (29-62)	0.496
Platelets (× 10⁴/μL)	13.5 ± 6.8	13.9 ± 4.7	13.9 ± 9.2	12.5 ± 4.4	0.804
Serum ALB (g/dL)	3.76 ± 0.39	3.94 ± 0.40	3.67 ± 0.35	3.67 ± 0.38	0.006¹
PT (%)	89.8 ± 13.4	92.5 ± 11.4	87.8 ± 15.0	89.2 ± 13.5	0.254
Serum TBIL (mg/dL)	0.78 ± 0.34	0.74 ± 0.32	0.79 ± 0.33	0.81 ± 0.39	0.777
ICGR15	14.2 (8.4-18.5)	12.1 (8.1-15.4)	14.7 (8.4-21.5)	15.6 (13.0-24.6)	0.163
AFP (ng/mL)	18.6 (5.6-134.0)	5.3 (3.8-11.0)	21.1 (6.9-99.2)	299.7 (68.1-1046.0)	< 0.001¹
DCP (mAU/mL)	45 (21-244)	22 (15-35)	37 (23-134)	429 (124-1902)	< 0.001¹
Intraoperative data
Blood loss (mL)	330 (20-650)	263 (70-500)	230 (20-500)	535 (300-1270)	0.006¹
Surgical duration (min)	304 (230-377)	303 (175-377)	296 (230-352)	345 (282-475)	0.040¹
Blood transfusion
RCC: yes/no (%)	12/88 (12.0%)	3/31 (8.8%)	2/37 (5.1%)	7/20 (25.9%)	0.030¹
Pathologic results
Tumor size (cm)	3.51 ± 2.48	2.84 ± 1.23	3.26 ± 2.31	4.72 ± 3.39	0.008¹
Multiple tumor: yes/no (%)	36/64 (36.0%)	8/26 (23.5%)	17/22 (43.6%)	11/16 (40.7%)	0.171
Vascular invasion: yes/no (%)	30/70 (30.0%)	5/29 (14.7%)	12/27 (30.8%)	13/14 (48.1%)	0.018¹
Remnant liver: NL/CH/LC	5/37/58	2/18/14	2027/10/2	2017/9/1	0.161
Histological tumor differentiation
Well/Moderately/Poorly	17/63/20	7/23/4	8/24/7	2/16/9	0.213
Recurrence within 2 yr after hepatectomy
Yes/no (%)	51/49 (51.0%)

¹Represents statistically significance. Data are presented as medians (25^th-75^th percentile range) for skewed distribution and mean ± SD for normal distribution. LL group: AFP values < 21.0 ng/mL and DCP values < 67 mAU/mL; HL group: AFP values < 21.0 ng/mL or DCP values < 67 mAU/mLF; HH group: AFP values < 21.0 ng/mL and DCP values < 67 mAU/mL; Open group: Open laparotomy group; Lap group: Laparoscopic hepatectomy group; Pure Lap: Pure laparoscopic hepatectomy; Lap-assisted, laparoscopy-assisted hepatectomy; Hr0: Partial hepatectomy; HrS: Sub-segmentectomy; Hr1: Sectionectomy; Hr2: Bisegmentectomy; Hr3: Trisegmentectomy. ALB: albumin; PT: prothrombin; TBIL: total bilirubin; ICGR15: indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; DCP: Des-γ-carboxy prothrombin.

Table 5 Univariate and multivariate analyses of factors associated with tumor recurrence in patients with hepatitis C virus infection

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95%CI	P value	HR	95%CI	P value
Age	1.001	0.972-1.031	0.950
Sex, male	1.455	0.823-2.570	0.197
Preoperative laboratory values
Aspartate transaminase	1.005	0.999-1.011	0.134
Alanine transaminase	1.003	0.966-1.010	0.412
Platelets	1.015	0.983-1.049	0.363
Serum ALB	0.569	0.297-1.092	0.090
PT	0.999	0.980-1.019	0.943
Serum TBIL	1.281	0.610-2.692	0.513
ICGR15	1.049	1.017-1.081	0.002¹	1.069	1.032-1.108	< 0.001¹
Tumor markers
HH group	4.427	2.238-8.760	< 0.001¹	5.098	2.165-12.005	< 0.001¹
HL group	2.210	1.166-4.189	0.015¹	2.325	1.077-5.018	0.032¹
Intraoperative data
Blood loss	1.001	1.000-1.001	< 0.001¹	1.000	0.999-1.000	0.292
Surgical duration	1.003	1.002-1.004	< 0.001¹	1.002	0.998-1.006	0.129
Pathologic results
Tumor size	1.290	1.178-1.413	< 0.001¹	1.160	1.033-1.302	0.012¹
Multiple tumors	1.264	1.073-1.487	0.005¹	1.264	1.041-1.534	0.018¹
Vascular invasion	2.454	1.479-4.071	0.001¹	1.597	0.890-2.867	0.117

¹Represents statistical significance. HH group: Alpha-fetoprotein values > 21.0 ng/mL and des-gamma-carboxy prothrombin values > 67 mAU/mL; HL group: Alpha-fetoprotein values > 21.0 ng/mL or des-gamma-carboxy prothrombin values > 67 mAU/mL. ALB: Albumin; PT: Prothrombin; TBIL: Total bilirubin; ICGR15: Indocyanine green retention rate at 15 min.

Table 6 Univariate and multivariate analyses of factors associated with poor overall survival in patients with hepatitis C virus infection

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95%CI	P value	HR	95%CI	P value
Age	1.025	0.987-1.065	0.195
Sex, male	1.328	0.668-2.642	0.418
Preoperative laboratory values
Aspartate transaminase	1.006	0.999-1.013	0.106
Alanine transaminase	1.001	0.992-1.009	0.849
Platelets	1.036	0.995-1.077	0.084
Serum ALB	0.246	0.114-0.531	< 0.001¹	0.611	0.219-1.706	0.347
PT	0.994	0.971-1.018	0.643
Serum TBIL	1.206	0.523-2.780	0.660
ICGR15	1.054	1.021-1.087	0.001¹	1.042	1.001-1.084	0.047¹
Tumor markers
HH group	4.562	2.031-10.248	< 0.001¹	4.018	1.424-11.337	0.009¹
HL group	2.049	0.911-4.609	0.083	2.209	0.829-5.885	0.113
Intraoperative data
Blood loss	1.001	1.000-1.001	< 0.001¹	1.000	0.999-1.001	0.727
Surgical duration	1.003	1.002-1.004	< 0.001¹	1.002	0.998-1.005	0.414
Pathologic results
Tumor size	1.285	1.162-1.421	< 0.001¹	1.081	0.946-1.235	0.255
Multiple tumors	1.204	1.021-1.420	0.027¹	1.257	1.025-1.542	0.028¹
Vascular invasion	2.223	1.221-4.045	0.009¹	1.089	0.490-2.421	0.835

Citation: Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945
URL: https://www.wjgnet.com/1007-9327/full/v21/i16/4933.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i16.4933